Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.7.0.1
Significant Accounting Policies (Details Narrative)
12 Months Ended
Apr. 08, 2015
USD ($)
Mar. 09, 2015
USD ($)
Dec. 31, 2016
USD ($)
Breathlyzers
Dec. 31, 2015
USD ($)
Allowance for doubtful accounts receivable     $ 1,010,196 $ 864,000
Allowances charged for doubtful accounts     $ 146,196 864,000
Concentration risk percentage     10.00%  
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture $ 64,091 $ 64,675    
Percentage of ownership in Hainan Savy Akers Biosciences, Ltd. joint venture   19.90%    
Deferred revenue     $ 41,120 233,542
Accrued rebates     471,949 438,360
Shipping, handling and transportation costs     54,928 56,537
Cost of net revenue     $ 138,662 115,423
Trade Receivable [Member]        
Concentration risk percentage     75.00%  
Concentration risk, number of customer | Breathlyzers     3  
Percentage of customer accounted for trade receivables     30.00%  
Fulton Bank of New Jersey [Member]        
Cash     $ 67,865 369,525
Bank of America [Member]        
Cash     795 28,494
PayPal [Member]        
Cash     $ 4,040 $ 4,040
Minimum [Member]        
Normal credit terms extended to customers     30 days  
Maximum [Member]        
Normal credit terms extended to customers     90 days  
Cash, FDIC insured amount     $ 250,000  
Maximum [Member] | Patents [Member]        
Finite-lived intangible asset, useful life     17 years